FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 12:14:59 10/05/2024 BST | ||
| 67.61 EUR | -1.63% |
|
| Current month | -10.51% | ||
| 1 month | +11.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 67.61 | -1.63% | 0 |
| 09/05/24 | 68.73 | +3.93% | 0 |
| 08/05/24 | 66.13 | -1.03% | 0 |
| 07/05/24 | 66.82 | +15.35% | 0 |
| 06/05/24 | 57.93 | +7.02% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 12:14 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SQ70TG |
| ISIN | DE000SQ70TG3 |
| Date issued | 17/01/2023 |
| Strike | 935.4 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 115.6 € |
|---|---|
| Lowest since issue | 6.61 € |
| Spread | 4.48 € |
| Spread % | 6.21% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat
